Sign in
Not yet taking people in United StatesNo phase

Almonds for Vitamin E and Diet Quality in People Taking GLP-1 Medicines

Tests daily almonds in people with obesity or type 2 diabetes using GLP-1 treatment.

Key facts

Who runs it
Pennington Biomedical Research Center
Where
Baton Rouge, United StatesSee the site
Trial code
Registry title
Ability of Almonds to Improve Nutrition During GLP-1 Treatment
Status
Not yet recruiting
People taking part
76 people, planned
Started
3 Sept 2026
Expected to end
1 Dec 2028
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Almond Diet
Record updated
1 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-70 with obesity or type 2 diabetes who are prescribed injectable semaglutide or tirzepatide. It tests whether eating almonds improves vitamin E levels and diet quality.

Age
18 to 70 years
Sex
All sexes can join.
Disease stage
Obesity (BMI ≥ 30 kg/m2), or type 2 diagnosed by a doctor with BMI ≥ 27 kg/m2 - 47.5 kg/m2.
Earlier treatment
Prescribed branded injectable semaglutide or injectable tirzepatide, with at least a two-month supply. Baseline tests must be done before starting it. No GLP-1 medication in the last 3 months.

Main reasons for not taking part

  • Pregnancy or breastfeeding
  • Taking or planning a medication, vitamin or mineral supplement that affects vitamin E levels
  • Allergic to almonds
  • History of bariatric surgery
  • Active malignancy, except some skin cancers, or chemotherapy/radiotherapy

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Adults aged 18-70 years
  • BMI ≥ 27 kg/m2 - 47.5 kg/m2 and diagnosed with type 2 diabetes by their personal physician (e.g., primary care physician, endocrinologist), or BMI ≥ 30 kg/m2 and have obesity and stable access (i.e., at least a two-month supply) to the medication
  • Prescribed branded injectable semaglutide or injectable tirzepatide (medication will not be provided as part of the study)
  • HbA1c will be measured at Pennington Biomedical at baseline (and follow-up), though the baseline HbA1c levels from Pennington Biomedical will not be used for eligibility criteria
  • Use of other medications (diabetes medications or otherwise) are permitted at the discretion of the Medical Investigator
  • Enroll and complete baseline assessments prior to starting pharmacotherapy
  • Able and willing to adhere to all study-related procedures

Who cannot take part

  • Taking or planning to take during the trial a medication, vitamin, or mineral supplement that affects vitamin E levels
  • Previous use of a glucagon-like peptide-1 medication in the last 3 months
  • Contraindications to glucagon-like peptide-1 medication use or previous adverse reaction/allergy to a glucagon-like peptide-1 receptor agonist medication
  • Medical, psychological, cognitive, or other conditions that limit the ability to complete study procedure
  • History of bariatric surgery
  • Allergic to almonds
  • Active malignancy, excluding some skin cancers, or undergoing chemotherapy/radiotherapy
  • Pregnancy or breastfeeding

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

  • Pennington Biomedical Research CenterBaton Rouge, United StatesContact: Corby K Martin, PhDNot yet recruiting

About the trial

What the trial wants to find out

This 8-week randomized controlled pilot trial is to test the hypothesis that, compared to a Usual Diet control group, almond intake will increase vitamin E (alpha-tocopherol) levels in the blood and improve diet quality (Healthy Eating Index) among people prescribed a glucagon-like peptide-1. Two groups of individuals will either: 1) consume a minimum of 56 grams of almonds each day, or 2) not consume almonds and follow their usual diet.

The 2 groups in the trial

  • Almond Diet GroupTreatment being tested

    This group will be provided with up to 84 grams per day of raw or roasted almonds per day and coached to consume at least 56 grams/day. Participants will be instructed to consume the almonds by replacing snacks, particularly those high in refined carbohydrate, with almonds; integrating almonds into other snacks and meals, etc. 56 grams/day of almonds is equivalent to two servings, which reflects the adult Dietary Guidelines for Americans and is consistent with doses that have been shown to increase alpha-tocopherol levels, and produce beneficial effects on cardiometabolic health and nutrient intake.

    Treatment: Almond Diet

  • Usual Diet ControlNo study treatment, for comparison

    This group will not be provided with any food products and will not receive dietary advice, except being asked to abstain from eating nuts during the 8-week trial. They will receive a weekly phone call from the study team to foster retention and to control the number of contacts between the study team and each of the two groups in the trial.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Ability of Almonds to Increase Vitamin E (Alpha-tocopherol) and Diet Quality During GLP-1 Treatment: A Randomized Controlled Pilot Trial
Plain-language title
Almonds for Vitamin E and Diet Quality in People Taking GLP-1 MedicinesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Fit questions
Built from NCT07796204, who can take part
Record updated
1 September 2026